Patterns of genetic alterations could guide management.
The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response.
Halozyme Therapeutics announced that the phase 3 HALO-301 study of PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreatic cancer has failed to meet the primary end point of overall survival.
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Exceeding tolerances of healthy organs-at-risk as a result of daily anatomical deformations is a concern for patients with LAPC treated with SBRT.
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall.
Patients who had tumors measuring 1.5 cm to 2 cm were at double the risk for lymph node metastasis.
As cancer treatments become more complex, tumor boards can help simplify options.